The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD).
Matthew Chan
No relevant relationships to disclose
Lauren Haydu
No relevant relationships to disclose
Alexander M. Menzies
Other Remuneration - GlaxoSmithKline; Roche
Mary W. F. Azer
No relevant relationships to disclose
Oliver Klein
No relevant relationships to disclose
Alexander Guminski
Honoraria - Roche
Richard Kefford
Consultant or Advisory Role - GlaxoSmithKline; Roche
Georgina Long
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche
Honoraria - Roche